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Objective: 18F-Fluciclovine (FACBC) is an amino acid 
PET radiotracer approved for recurrent prostate cancer 
imaging. We investigate the use of Bayesian penalised 
likelihood (BPL) reconstruction for 18F-fluciclovine PET.
Methods: 15 18F-fluciclovine scans were reconstructed 
using ordered subset expectation maximisation (OSEM), 
OSEM + point spread function (PSF) modelling and BPL 
using β-values 100–600. Lesion maximum standardised 
uptake value (SUVmax), organ SUVmean and standard 
deviation were measured.Deidentified reconstructions 
(OSEM, PSF, BPL using β200–600) from 10 cases were 
visually analysed by two readers who indicated their 
most and least preferred reconstructions, and scored 
overall image quality, noise level, background marrow 
image quality and lesion conspicuity.
Results: Comparing BPL to OSEM, there were significant 
increments in lesion SUVmax and signal-to-background 
up to β400, with highest gain in β100 reconstructions 
(mean ΔSUVmax 3.9, p < 0.0001). Organ noise levels 
increased on PSF, β100 and β200 reconstructions. 
Across BPL reconstructions, there was incremental 
reduction in organ noise with increasing β, statisti-
cally significant beyond β300–500 (organ-dependent). 
Comparing with OSEM and PSF, lesion signal-to-noise 
was significantly increased in BPL reconstructions 
where β ≥ 300 and  ≥ 200 respectively.On visual analysis, 
β 300 had the first and second highest scores for image 
quality, β500 and β600 equal highest scores for marrow 
image quality and least noise, PSF and β 200 had first 
and second highest scores for lesion conspicuity. For 
overall preference, one reader preferred β  300 in 9/10 
cases and the other preferred β 200 in all cases.
Conclusion: BPL reconstruction of 18F-fluciclovine PET 
images improves signal-to-noise ratio, affirmed by overall 
reader preferences. On balance, β300 is suggested for 
18F-fluciclovine whole body PET image reconstruction 
using BPL.
Advances in knowledge: The optimum β is different 
to that previously published for 18F-fluorodeoxyglu-
cose, and has practical implications for a relatively new 
tracer in an environment with modern reconstruction 
technologies.
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intRODuCtiOn
The optimisation of Bayesian penalised likelihood (BPL) 
reconstruction (Q.Clear, GE Healthcare) for 18F-fluoro-
deoxyglucose (FDG) whole body PET,1 and its effect on 
evaluating various clinical entities on 18F-FDG PET/CT 
have been reported.2–5 BPL runs to effective convergence 
and includes point spread function (PSF) modelling while 
controlling noise through the use of a penalty term (β), 
which achieves greater noise reduction as β is increased.1 
It has been shown to improve lesion signal-to-noise ratio 
(SNR) on 18F-FDG PET compared to widely utilised 
ordered subset expectation maximisation (OSEM) recon-
struction, particularly in small, subcentimetre abnormal-
ities.2 Our institution currently uses BPL reconstructed 
images (β = 400)1 for the clinical interpretation of all 18F-
FDG whole body PET/CT studies.
The burgeoning repertoire of non-FDG PET tracers coupled 
with progressive adaptation of modern image reconstruc-
tion technology demands tracer-specific optimisation of its 
use. This is due to inherent variation of physiological distri-
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different tracers. More importantly, the practice of image opti-
misation remains paramount to maintaining duty of care to the 
patient.
18F-Fluciclovine (anti-1-amino-3-fluorocyclobutane-1-carbox-
ylic acid/FACBC) is a synthetic amino acid PET radiotracer 
with expectant clinical demand, followed recent approvals by 
the Food and Drug Administration and European Medicines 
Agency as a diagnostic agent for detection of recurrent prostate 
cancer.6,7 The aim of this study was to compare BPL to standard 
PET reconstruction of 18F-fluciclovine images and determine 




This study was approved by the South Central Berkshire Research 
Ethics Committee. Fifteen 18F-fluciclovine whole body scans 
performed consecutively between October 2015 and August 
2016 for biochemical recurrence of prostate cancer were retro-
spectively selected. The median patient weight was 77.3 kg (range 
56–102 kg).
18F-Fluciclovine PET/CT imaging protocol
Image acquisition was performed on a 3D-mode time-of-flight 
GE Discovery 710 PET/CT system (GE Healthcare, Milwaukee, 
WI). Patients were required to fast for at least 4 h before injec-
tion. Imaging commenced 3–5 min post-injection of 18F-fluci-
clovine (327 to 418 MBq) covering the skull base to proximal 
thighs. PET images were acquired under normal tidal respira-
tion, commencing caudally, for 5 min per bed position for the 
first two bed positions (over the pelvis), and 3 min per bed posi-
tion for the remaining acquisition.
Semi-quantitative analysis
Sinograms of the 15 scans were reconstructed using three 
different algorithms, each of which used the CT scan for atten-
uation correction and the same normalisation correction factors 
with scatter and randoms corrected as has been previously 
described.8 The first algorithm was OSEM (ToF OSEM, VPFX, 
GE Healthcare), used with 2 i, 24 ss and 6.4 mm filter. The second 
was using OSEM + PSF, henceforth referred to as PSF (ToF 
OSEM PSF, 3 i, 24 ss, 2 mm filter),1 and the third was BPL using a 
range of penalisation factors (β): 100, 200, 300, 400, 500 and 600.
The following parameters were measured on each of the recon-
structions: lesion maximum standardised uptake value (SUVmax), 
SUVmean and standard deviation (SUVdev, noise) of reference 
organs (marrow, spleen, blood pool, liver). Lesions were defined 
as small foci of presumed local or distant recurrence. SUVmax 
of each lesion was recorded using a standard volume of interest 
(VOI) tool. Organ SUVs were measured as follows: marrow–L3 
vertebra using a 1.5 cm edge cube VOI, spleen–interpolar region 
using a 2.0 cm diameter spherical VOI, blood pool–mid-thoracic 
aorta using a 1.0 cm diameter, 2.0 cm long cylindrical VOI, liver–
right lobe of liver using a 3.0 cm diameter spherical VOI. SNR 
and signal-to-background ratio  (SBR) were calculated. Lesion 
SNR was defined as lesion SUVmax divided by marrow SUVdev. 
Lesion SBR was defined as lesion SUVmax divided by marrow 
SUVmean. Marrow uptake was used for normalisation based on 
the moderate and heterogeneous 18F-fluciclovine uptake seen in 
this organ. Organ SNR was calculated as organ SUVmean divided 
by organ SUVdev.
Statistical analysis
Statistical comparisons were made with reference to both OSEM 
and PSF, using repeated measures ANOVA with Dunnett’s 
multiple comparison post-hoc testing. Statistical analyses were 
performed using GraphPad Prism v. 7.0 a (GraphPad Software, 
La Jolla, CA). Differences in SUV were denoted by “ΔSUV”. 
p-values < 0.05 were considered to be statistically significant. 
Inter-reader agreement in the visual analysis was evaluated using 
weighted Cohen’s κ with linear weights. κ values were interpreted 
using guidelines laid out by Landis and Koch.9
Clinical evaluation—reconstruction and visual 
analyses
Ten of the 15 scans were used for this component of the study. 
Visual analyses of the OSEM, PSF, BPL β200–600 reconstruc-
tions, were performed by two consultants (designated Reader 1 
and 2) with dual accreditation in clinical radiology and nuclear 
medicine, both with more than 10 years of nuclear medicine 
subspecialty experience. Having previously described similari-
ties between BPL β100 and PSF in (greater) image noise,1 reaf-
firmed by subsequent results of the semi-quantitative analysis, 
β100 was omitted from the visual analyses.
The reconstructions were labelled A to G in a randomised 
order, with the CT component available for image fusion and 
non-attenuation corrected images for reference. Cases were 
reviewed sequentially, and reconstructions were scored (from 1 
to 5) according to four image quality parameters: overall image 
quality, lesion conspicuity, overall noise level and marrow image 
quality. Readers were provided with guidance on features which 
should constitute each score (Table 1). For every reconstruction, 
a final score for each parameter was derived from the sum of 
scores given to the relevant parameter for the particular recon-
struction. For example, the final score for lesion conspicuity in 
OSEM would be a sum of the individual scores for this parameter 
in OSEM reconstructions across the 10 cases.
Readers indicated their most and least preferred reconstruc-
tion for each case. Proportions of the highest and lowest ranked 
reconstructions were calculated for each parameter.
RESultS
Results for the semi-quantitative analyses are summarised in 
Figures 1–4, and a representative image for each reconstruction 
is presented in Figure  5. Compared to OSEM, lesion SUVmax 
and SBR increased in β100–400 and PSF, with highest gain in 
β100 reconstructions (mean ΔSUVmax 3.9, p < 0.0001) (Figure 1). 
Lesion SNR was increased in BPL reconstructions compared to 
OSEM where β ≥ 300 (Figure 1), with no significant intergroup 
difference between β300–600 (p = 0.562). When compared to 
PSF, lesion SNR was increased in all BPL reconstructions (p = 
0.0001–0.021), with the exception of β100.
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Table 1. Scoring system applied to the four image quality parameters in the visual analysis
Score Overall image quality/lesion conspicuity Overall noise level (excluding marrow)/background marrow image quality
1 Not reportable Non-diagnostic
2 Poor Numerous heterogeneities throughout entire study, reduced diagnostic quality
3 Satisfactory Numerous small heterogeneities
4 Good Minimal heterogeneities
5 Excellent No significant noise
Figure 1. Graphs of lesion SUVmax, SBR and SNR across the different reconstructions (mean ± standard deviation, dotted line 
represents mean value on OSEM reconstruction). Statistical comparisons to OSEM are represented above the data points, and 
comparisons to PSF are represented  below the data points (*p < 0.05, **p ≤ 0.01, ***p ≤ 0.001, ****p ≤ 0.0001). OSEM, ordered 
subset expectation maximisation; SBR, signal-to-background ratio; SNR, signal-to-noise ratio; SUV, standardised uptake value.
Comparing to OSEM, there was no change in SUVmean of 
spleen and blood pool across all reconstructions (Figure  2). 
While such changes in the liver and marrow were statistically 
significant (Figure 2), these were deemed clinically insignifi-
cant (highest ΔSUVmean: 0.052 in liver, 0.154 in marrow). There 
was no change in SUVmean of all the organs when comparison 
was made to PSF.
Across the BPL reconstructions, there was an incremental 
reduction in organ noise with increasing β, which compared to 
OSEM, were significant beyond β300–500 (organ-dependent) 
(Figure  3). Compared to OSEM, organ noise levels increased 
on PSF, β100 and β200 reconstructions (Figure  3). This trend 
was also demonstrated in organ SNR, with statistically signifi-
cant gains (over OSEM) in marrow, liver and blood pool when 
β ≥ 400, and the spleen when β ≥ 300 (Figure 4). The opposite 
trend was observed when comparisons were made to PSF where 
noise was significantly lower, and SNR significantly higher, in all 
organs where β ≥ 200 (Figures 3 and 4).
In the clinical evaluation, there was moderate agreement in 
scores between the two readers [κ = 0.48, 95% CI (0.40–0.56)]. 
β300 had the first and second highest scores (between both 
readers) for overall image quality, PSF and β200 had first and 
second highest scores for lesion conspicuity, β500 and β600 had 
joint highest scores for marrow image quality and overall noise 
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Figure 2. Graphs of organ SUVmean (mean ± standard deviation, dotted line represents mean value on OSEM reconstruction). 
While there were statistically significant differences between OSEM and the other reconstructions in the liver and marrow (high-
est ΔSUVmean 0.052 and 0.154 respectively), these were deemed clinically insignificant. Statistical comparisons to OSEM are 
represented in blue above the data points, and comparisons to PSF are represented in red below the data points (*p < 0.05, 
****p ≤ 0.0001). OSEM, ordered subset expectation maximisation; PSF, point spread function; SUV, standardised uptake value.
level (i.e. least noise) (Table  2). These findings complemented 
those of the semi-quantitative analyses.
In terms of overall preferences, Reader 1 preferred β300 in 90% 
of cases and Reader 2 preferred β200 in all cases. There was a 
greater polarisation of opinion with regards to least preferred 
reconstructions, with Reader 1 indicating PSF in 80% and Reader 
2 chose β600 in 90% of cases.
DiSCuSSiOn
The aim of this study was to compare BPL to standard PET recon-
struction of 18F-fluciclovine images and determine the optimum 
penalisation factor (β) for clinical use of BPL in 18F-fluciclovine 
whole body imaging. This was addressed using a combination of 
semi-quantitative and visual analyses performed on a range of 
reconstructions of clinical scans.
Consistent with prior observations,1–5 the majority of BPL recon-
structions demonstrated an increase in lesion signal and reduc-
tion in noise over OSEM. While lesion signal was higher in the 
PSF reconstruction compared to BPL reconstructions β ≥ 200, 
this came at a significant detriment to image noise, which was 
consistently lower in these BPL reconstructions (β ≥  200) and 
widely used OSEM reconstruction (Figure  3). This reinforces 
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Figure 3. Graphs of organ SUVdev (mean ± standard deviation, dotted line represents mean value on OSEM reconstruction). Statis-
tical comparisons to OSEM are represented in blue above the data points, and comparisons to PSF are represented in red below 
the data points (*p < 0.05 **p ≤ 0.01, ***p ≤ 0.001, ****p ≤ 0.0001). OSEM, ordered subset expectation maximisation; PSF, point 
spread function; ; SUV, standardised uptake value.
observations from our prior work and others,1,10 and is the 
basis for non-adoption of PSF in our institution when initially 
released.
The increase in lesion signal (SUVmax, SBR) compared to OSEM 
reached statistical significance in the BPL reconstructions up 
to β400 (Figure 1), while that of noise level showed a decrease 
in three out of four organs (one statistically significant) at 
β300 (Figure  3). At β400 and higher, noise was decreased in 
all organs compared to OSEM (three statistically significant 
at β400, Figure 3). Accordingly, an increase in lesion SNR was 
demonstrated in all reconstructions at β300 and higher, with 
no statistical advantage on semi-quantitative parameters, of one 
reconstruction over the other beyond this point (Figure 1). These 
collective findings tentatively placed either β300 or β400 as the 
optimal BPL reconstruction setting.
The visual analysis proved useful in stratifying this outcome. 
Between the readers, β300 had the first and second highest 
scores for overall image quality of clinical scans, while β400 
scored second and third highest respectively. This trend was 
also mirrored in scoring of lesion conspicuity where, after PSF 
and β200 (which demonstrate a detrimental increase in noise 
despite signal gain), β300 was scored higher than β400 by both 
readers.
β300 was indicated as the most preferred reconstruction in 9 out 
of 10 cases by one reader. On balance, the relatively minor differ-
ence in overall reader preference is deemed relatively immaterial 
to the strength of the other overarching findings. Therefore, β300 
should be considered as the optimal penalisation factor for BPL 
reconstruction of 18F-fluciclovine PET images. A case example is 
presented in Figure 6.
Our findings are important because the use of newer PET recon-
struction algorithms incorporating PSF modelling such as BPL 
may have implications for the interpretation of oncological PET/
CT, particularly as it has been shown to increase sensitivity at 
a cost of reduced specificity for a given SUV threshold.2 Adop-
tion of new reconstruction algorithms into well-established clin-
ical practice, notably with interpreting 18F-FDG PET, demands 
dedication on the part of the reader to recalibrate their approach 
to reading studies. Widespread adoption of advanced recon-
struction algorithms is challenging due to the highly variant 
experience with 18F-FDG PET reconstruction across the globe, 
which has been in constant iteration since the use of filtered back 
projection and 2D-mode scanning.
The landscape is encouragingly different with 18F-fluciclovine, 
which has recently been approved for a focused clinical indica-
tion (recurrent prostate cancer), with interpretation guidelines 
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Figure 4. Graphs of organ SNR across the different reconstructions (mean ± standard deviation, dotted line represents mean value 
on OSEM reconstruction). Statistical comparisons to OSEM are represented in blue above the data points, and comparisons to PSF 
are represented in red below the data points (*p < 0.05, **p ≤ 0.01, ***p ≤ 0.001, ****p ≤ 0.0001). OSEM, ordered subset expectation 
maximisation; PSF, point spread function; SNR, signal-to-noise ratio; SUV, standardised uptake value.
Figure 5. Axial images at the level of the pubic symphysis. Different reconstructions demonstrating a subcentimetre  
18F-fluciclovine-avid focus of disease (arrow) in the anterior prostatectomy bed. Consistent with the semi-quantitative results, 
the lesion is rendered more conspicuous on BPL reconstructions with relatively less background noise. All images are displayed 
on SUV scale 0–6. OSEM, ordered subset expectation maximisation; PSF, point spread function; SUV, standardised uptake value.
built on cumulative experience of a small consortia of readers 
using relatively modern scanner and reconstruction tech-
nology.11,12 Furthermore, being an amino acid, it may be less 
fallible to non-specific uptake by inflammatory/benign entities 
compared to 18F-FDG as described in vitro,13 and anecdotally in 
published literature.14,15
The difference in optimal β compared to 18F-FDG whole body 
PET, previously described to be β400,1 can be explained by the 
differences in physiological distribution and pathological uptake 
compared to 18F-fluciclovine. In prostate cancer, nodal recur-
rence tends to occur within the pelvis and retroperitoneum, 
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Table 2. Scores of image quality parameters in the visual analysis 
Reconstruction
Overall image quality Lesion conspicuity Overall noise level Background marrow image quality
Reader 1 Reader 2 Reader 1 Reader 2 Reader 1 Reader 2 Reader 1 Reader 2
OSEM 34 37 19 20 43 36 44 39
PSF 27 39 30 29 22 21 21 20
β 200 36 50 30 28 33 33 31 29
β 300 50 47 27 22 44 39 44 33
β 400 45 40 22 22 49 45 49 41
β 500 39 30 21 16 50 50 50 50
β 600 36 30 19 15 50 50 50 50
OSEM, ordered subset expectation maximisation; PSF, point spread function.
For every reconstruction, a final score for each image quality parameter was derived from the sum of scores given to the relevant parameter for 
the particular reconstruction.
Figure 6. Maximum intensity projection images (SUV scale 0–7) of a patient demonstrating small foci of disease recurrence in 
the pelvis and left femoral head, rendered more conspicuous on the BPL β 300 reconstruction compared to OSEM, but without 
the penalty of increased noise depicted on the PSF reconstruction. OSEM, ordered subset expectation maximisation; PSF, point 
spread function; SUV, standardised uptake value.
where adjacent background uptake is relatively low. Improved 
demonstration of pathological uptake, particularly in small 
nodes, would then be afforded by a relatively low β, which gener-
ates increased signal at minimal penalty to surrounding back-
ground noise.
Being in the early stages of clinical rollout, there is an opportu-
nity for naïve readers to gain their formative clinical experience 
with 18F-fluciclovine interpretation based on advanced image 
reconstruction from the start. Apart from affording a step-up in 
patient care, through improved image quality and confidence in 
interpretation, this should avoid the unnecessary complexities 
of relearning should current mainstream reconstruction tech-
nology get eclipsed.
Our experience with this process supports an ongoing collabo-
rative effort amongst academic leaders and industry involved in 
this and other novel radiotracers, to maintain clear interpretation 
guidelines based on collective experience with different recon-
struction technologies. This has to be supported by prospective 
study of diagnostic performance based on advanced reconstruc-
tion technology, and retrospective evaluation of the like where 
possible, using the same approach as this study, exploiting saved 
sinogram data. We also propose these actions for forthcoming 
imaging agents as they attain regulatory approval.
There are limitations to consider in this study. It was not possible 
to completely blind the scorers to the different reconstruction 
algorithms, as BPL has a different visual appearance compared 
to PSF at all -values, and to OSEM to a limited extent. This may 
have introduced bias as readers progressed through the scoring 
process, mitigated to some extent by the wide range of BPL 
reconstructions used. Finally, caution should be adopted in the 
event of expanded clinical use for 18F-fluciclovine, and revisiting 
optimisation of image reconstruction based on disease type and/
or organ of interest, particularly the brain, may be warranted.
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COnCluSiOn
BPL reconstruction of 18F-fluciclovine PET images improves 
SNR, affirmed by overall reader preferences for BPL reconstruc-
tions. On balance, β300 is suggested for 18F-fluciclovine whole 
body PET image reconstruction using BPL.
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